»¶ÀÖ¶·µØÖ÷_Õ©½ð»¨ÓÎÏ·

YANG Chengsheng, HUANG Shipu, LlU Jiayi, HUANG Weiguo

(College of Basie Medicine, Guilin Medical University, Guilin 541199, China)

Nasopharyngeal carcinoma ( NPC )is the most common malignant tumor in head and neck region. InAbstractrecent years, breakthrough progress has been made in immune checkpoint inhibitors ( ICls) based on programmeddeath-1/programmed death ligand-1 ( PD-1/PD-L1 ) blockade, and PD-1 inhibitors have been approved for thetreatment of recurrent and/or metastatic NpC. At present, Pl-l immune checkpoint inhibitors have become the mainmethod of NPC immunotherapy, and other immunotherapies inelude tumor vaccines, cytokines, therapeuticantibodies , molecular targeted therapy, etc. NPC immunotherapy improves the body's immunity, reduces the sideelfects of therapy, and improves quality of life for patients. Many clinical studies have investigated the safety andeffectiveness of immunotherapy in the therapy of advanced NPC. Significant progress has been made in the immunotherapy of NPC, and multiple clinical studies on immunotherapy have achieved success in terminal NPC.Based on literature research, this article reviews the principles, main methods, and existing problems of NPCimmunotherapy from three aspects: tumor immunotherapy, NPC immunotherapy methods, and the shortcomings ofNPC immunotherapy. The aim of this article is to provide the best plan for immunotherapy of NPC.Keywords: nasopharyngeal carcinoma ; immunotherapy; programmed death-l; immune evasion

DOI:10.19296/j.cnki.1008-2409.2024-02-005

PDFdownload£ºclick to download